On August 30, 2017, the FDA approved Kymriah, a CAR-T cell therapy for B-cell acute lymphoblastic leukemia — the first gene-modified cell therapy ever approved in the United States. Seven weeks later came Yescarta. Two months after that, Luxturna became the first FDA-approved gene therapy for an inherited disease. In the space of four months, an entire therapeutic category went from theoretical to commercial. By the end of 2024, 24 cell and gene therapies had reached approval, the pace of new approvals had roughly tripled, and more than 2,100 CGT clinical trials were active globally. Understanding how fast this field has actually moved — and why that pace creates a different kind of strategic and regulatory challenge than traditional biologics ever did — is foundational context for anyone operating in or around CGT today.
Why Does CGT’s Pace of Change Outrun Traditional Biologics?
Traditional biologics — monoclonal antibodies, recombinant proteins, vaccines — went through their own period of rapid regulatory and scientific evolution decades ago, but that evolution played out over a longer arc, giving regulatory frameworks, manufacturing standards, and commercial infrastructure time to mature alongside the science. CGT has compressed a comparable evolutionary arc into a fraction of the time. The approval count alone illustrates this: zero approved cell or gene therapies before 2017, three within the first year, and by 2024, a cumulative total of 24 — with the FDA approving as many as seven in a single year (2023).
This compression matters because regulatory frameworks, manufacturing standards, and commercial infrastructure cannot mature instantaneously alongside the science. A field moving this quickly is, almost by definition, operating with regulatory guidance, manufacturing best practices, and reimbursement models still being actively written even as products reach patients — a structural condition closer to the earliest days of biologics manufacturing than to the relatively mature regulatory environment biologics operate within today.
What Does the Actual Approval Timeline Show?
The shape of CGT approvals since 2017 tells its own story. The first three approvals — Kymriah and Yescarta in CAR-T, Luxturna in gene therapy — established proof of concept across two distinct modalities within months of each other. Zolgensma followed in 2019, the first systemically administered AAV gene therapy to reach approval. Then came a multi-year gap before the pace accelerated sharply: zero approvals in 2018, one in 2019, one in 2020, four in 2021, five in 2022, seven in 2023, and three in 2024 — 24 cumulative approvals across CAR-T, AAV gene therapy, lentiviral gene therapy, CRISPR-based gene editing, and tissue-engineered therapies.
This acceleration reflects more than just growing scientific confidence. It reflects the maturation of regulatory pathways specifically built to accommodate CGT’s unique development challenges — including the FDA’s Regenerative Medicine Advanced Therapy designation, which by the mid-2020s applied to more than 40 percent of CGT development programs and was associated with meaningfully faster paths to approval.
How Big Is the CGT Market Today, and Where Is It Headed?
As of 2024, the global CGT market generates approximately $10 to 11 billion in annual revenue, a roughly 280 percent increase from the field’s pre-commercial baseline in 2019. Three products — Yescarta, Kymriah, and Zolgensma — account for nearly half of total market revenue, reflecting both the strength of early movers and how concentrated commercial success has remained even as the approved-product count has grown. CAR-T therapies, concentrated in hematologic malignancies, represent the largest single share of current revenue, followed by AAV-based gene therapy addressing rare genetic diseases.
Looking forward, base-case projections put the CGT market at $27 to 44 billion by 2030 and $44 to 71 billion by 2035 — substantial growth, though more conservative than some of the more optimistic forecasts that circulated earlier in the field’s development. The more measured projection reflects persistent structural barriers the field has not yet fully resolved: manufacturing complexity and capacity constraints, the cost structure of one-time, multi-million-dollar therapies relative to existing reimbursement models, and the continued difficulty of translating CAR-T’s hematologic success into solid tumor indications, where biology has proven considerably less cooperative.
What Does the Clinical Pipeline Look Like Behind the Approved Products?
Approved products represent only a fraction of total CGT activity. As of the most recent industry data, more than 2,100 cell and gene therapy clinical trials are active globally, with the pipeline weighted heavily toward early-stage development — the majority of programs sit in Phase 1, reflecting how much of the field remains in active scientific and clinical validation even as commercial products multiply.
Gene editing represents the fastest-growing segment of this pipeline, with trial activity expanding roughly 400 percent in recent years as platforms beyond CRISPR-Cas9 — including base editing and prime editing approaches that avoid double-strand DNA breaks entirely — move toward clinical validation. Oncology remains the dominant indication category by trial volume, though the field has begun expanding meaningfully into new therapeutic areas: CNS disorders, metabolic disease, ophthalmology, neuromuscular conditions, and cardiovascular disease all now have active CGT programs, well beyond the hematologic malignancies and rare monogenic diseases where the field first proved itself commercially.
What Should This Pace of Change Mean for Companies Operating in CGT?
For any company developing, manufacturing, or commercializing within CGT, the practical implication of this pace is that strategic assumptions have a shorter shelf life here than they would in a more mature therapeutic category. A regulatory pathway considered standard practice eighteen months ago may have already been superseded by updated FDA guidance. A manufacturing approach considered state-of-the-art at one company’s IND filing may be measurably behind what a newer entrant is using by the time that same company reaches commercial scale.
This is also why CGT companies — across functions, not just R&D and regulatory — tend to need closer, more continuous engagement with the pace of change in their specific modality than companies in more established therapeutic categories typically require. A field that added more approved products in 2023 alone than existed in total before 2021 is not a field where last year’s competitive landscape, regulatory expectations, or manufacturing benchmarks can be safely assumed to still hold true today.